CA 15-3, TPA and CEA were assayed before surgery in 60 patients with breast cancer. A significant association was found between preoperative CA 15-3 levels and some of the most important prognostic factors in breast cancer, such as lymph node status and tumor size. No similar association was discovered for CEA and TPA.
Preoperative CA 15-3 levels were also significantly associated with early recurrences of the disease, thus adding useful information to prognosis especially in N + patients.
KufeD.W., InghiramiG., AbeM.Differential reactivity of a novel monoclonal antibody (DF3) with human versus benign breast tumors.Hybridoma1984; 3: 223–32.
2.
HilkensJ., HilgensJ., BijsF., HagemanP.H., ScholD., DoornewardG., Van der TweelJ.In: Peters H, ed. Monoclonal antibodies against human milkfat globule membranes useful in carcinoma research. Protides of the biological fluids.Oxford: Pergamon Press,1984; 31: 1013–6.
3.
ScheflerW.C.Statistics for health professionals.New York: Addison Wesley Publishing Company Inc, 1984.
4.
PetoR., PikeM.C., ArmitageP.Design and analysis of randomized clinical trials requiring prolonged observation of each patient.Br J Cancer1977, 35: 1–39.
5.
TormeyD., WaalkesT., SnyderJ.Biological markers in breast carcinoma. III Clinical correlations with carcinoembryonic antigen.Cancer1977; 39: 2397–404.
6.
Tormey, WaalkesT.Clinical correlation between CEA and breast cancer.Cancer1978; 42: 1507–11.
7.
LoprinziC., TormeyD., RasmussenP.Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.J Clin Oncol1986; 4: 46–56.
8.
BjorklundB.On the nature and clinical use of Tissue Polypeptide Antigen (TPA).Tumor Diagnostik1980; 1: 8–20.
9.
LutghensM., SchlegelG.CEA + TPA in clinical tumor diagnosis with special reference to breast cancer.Tumor Diagnostik1980; 1: 63–77.
10.
BezwodaW., DermanD., BothwellT.Significance of serum concentrations of CEA, ferritin, and calcitonin in breast cancer.Cancer1981; 48: 1623–8.
11.
SchapiraD., SchapiraM.Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer.Breast Cancer Res Treat1983; 3: 221–221.-4.
12.
ThompsonR.J., RuberyE., JonesH.M.Radioimmunoassay of serum creatine Kinase BB as a tumor marker in breast cancer.Lancet1980; 2: 673–5.
13.
StewartJ., RubensR., MillisR.Postoperative serum sialyltransferase levels and prognosis in breast cancer.Breast Cancer Res Treat1983; 3: 225–30.
14.
SakineH., OhnoT., KufeD.W.Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas.J Immunol1985; 135: 3610–5.
15.
HayesD.F., ZuraskiV.R., KufeD.W.Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer.J Clin Oncol1986; 4: 1542–50.
16.
ColomerR., SoleL.A., NavarroM., EncaboG., RuibalA., SalvadorL.CA 15-3: early results of a new breast cancer marker.Anticancer Res1986; 6(4): 683–4.
17.
NamerM., KrebsB.P., HeryM., AubanelD., KhaterR., FrenayM.CEA versus CA 15-3 as markers, for meta-stasized breast cancer.Proc Annu Meet Am Soc Clin Oncol1986; 5: 24–7.
18.
GionM., MioneR., DittadiR.Carcinoembryonic antigen, ferritin, tissue polypeptide antigen and CA 15-3 in breast cancer: relationship between carcinoma and normal breast tissue.Intern J Biol Markers1986; 1: 33–8.
